Russell A. Beliveau Sells 1,000 Shares of Maximus Inc. (MMS) Stock

Maximus Inc. (NYSE:MMS) Director Russell A. Beliveau sold 1,000 shares of Maximus stock in a transaction that occurred on Monday, April 2nd. The shares were sold at an average price of $66.55, for a total transaction of $66,550.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Shares of MMS stock opened at $65.59 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.57 and a current ratio of 2.57. The firm has a market capitalization of $4,356.92, a PE ratio of 21.01, a price-to-earnings-growth ratio of 2.31 and a beta of 1.12. Maximus Inc. has a 12 month low of $57.12 and a 12 month high of $72.71.

How to Become a New Pot Stock Millionaire

Maximus (NYSE:MMS) last announced its quarterly earnings data on Thursday, February 8th. The health services provider reported $0.78 EPS for the quarter, topping the Zacks’ consensus estimate of $0.77 by $0.01. The business had revenue of $623.10 million for the quarter, compared to analyst estimates of $624.36 million. Maximus had a net margin of 8.99% and a return on equity of 22.93%. The firm’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.71 earnings per share. analysts anticipate that Maximus Inc. will post 3.31 earnings per share for the current fiscal year.

A number of research analysts have weighed in on MMS shares. Canaccord Genuity reaffirmed a “buy” rating on shares of Maximus in a research note on Wednesday, December 27th. Zacks Investment Research raised shares of Maximus from a “sell” rating to a “hold” rating in a research note on Wednesday, January 17th. Finally, Maxim Group reissued a “hold” rating and issued a $69.00 price objective (up previously from $66.00) on shares of Maximus in a research report on Thursday, February 8th. One research analyst has rated the stock with a sell rating, five have given a hold rating and one has assigned a buy rating to the company. Maximus currently has a consensus rating of “Hold” and an average target price of $66.60.

Hedge funds have recently made changes to their positions in the company. Amundi Pioneer Asset Management Inc. bought a new stake in shares of Maximus in the fourth quarter worth $163,000. Steward Partners Investment Advisory LLC bought a new stake in shares of Maximus in the fourth quarter worth $169,000. Capital One National Association bought a new stake in shares of Maximus in the fourth quarter worth $213,000. Zeke Capital Advisors LLC bought a new stake in shares of Maximus in the fourth quarter worth $222,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Maximus by 51.3% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,581 shares of the health services provider’s stock worth $256,000 after purchasing an additional 1,214 shares in the last quarter. 96.71% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Russell A. Beliveau Sells 1,000 Shares of Maximus Inc. (MMS) Stock” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright law. The correct version of this piece can be viewed at

Maximus Company Profile

MAXIMUS, Inc provides business process services (BPS) to government health and human services programs in the United States, the United Kingdom, Australia, Canada, Singapore, and Saudi Arabia. The company's Health Services segment offers various BPS, appeals, and assessments, as well as related consulting services for state, provincial, and national government programs comprising Medicaid, Children's Health Insurance Program, the Affordable Care Act, Health Insurance British Columbia, the Health Assessment Advisory Service, and Preadmission Screening and Resident Reviews.

Insider Buying and Selling by Quarter for Maximus (NYSE:MMS)

Receive News & Ratings for Maximus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maximus and related companies with's FREE daily email newsletter.

Leave a Reply